Session » SLE – Treatment Poster III

Date: Monday, November 18, 2024

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2024

10:30AM-12:30PM: Abstract Number: 2440

Ambispective, Multicenter Registry of Treatment with Anifrolumab in Real Life in Patients with Systemic Lupus Erythematosus from Spanish Rheumatology Departments (ANIFRO-Reu): Efficacy, Safety and Patient’s Characteristics

10:30AM-12:30PM: Abstract Number: 2424

Anifrolumab Effects on Response to Influenza Vaccine in SLE

10:30AM-12:30PM: Abstract Number: 2427

Anti-CD19 Chimeric Antigen Receptor T Cell Therapy Induces Multicompartmental B Cell Depletion in Peripheral Blood, Bone Marrow and Lymph Nodes of Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 2437

Aryl Hydrocarbon Receptor as an Intrinsic Novel Checkpoint That Inhibits TLR7-induced B-cell Activation in SLE

10:30AM-12:30PM: Abstract Number: 2423

Associations Between Cytometric Interferon Signature and Clinical Response in a Cohort of Anifrolumab-treated Patients with Lupus

10:30AM-12:30PM: Abstract Number: 2435

Attainment of Remission, Use of Immunomodulatory/suppressive Agents and Gradual Dose Tapering May Facilitate Flare-free Withdrawal of Glucocorticoids in Patients with Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 2436

Characterization of RO7507062, a CD19-Targeting T-Cell Bispecific Antibody (CD19TCB), and Design of Its Ongoing Phase 1 Trial in Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 2430

Dapirolizumab Pegol Impacts Important Immunologic Pathways in Systemic Lupus Erythematosus: Pharmacodynamic Analysis of T Cell and Antigen Presenting Cell Pathways from a Phase 2b Trial

10:30AM-12:30PM: Abstract Number: 2422

Development of a Multiplexed-engineered, Off-the-shelf CAR NK Cell with Unique Multi-Pathogenic Cell Targeting Capacity for the Treatment of Autoimmune Diseases in the Absence of Conditioning Chemotherapy

10:30AM-12:30PM: Abstract Number: 2431

DORIS Remission in Patients with SLE Treated with Anifrolumab: Post Hoc Analysis from TULIP-1 and TULIP-2 Trials in Patents with No Reported History of Prior Immunosuppressant Use

10:30AM-12:30PM: Abstract Number: 2434

ESK-001, an Allosteric TYK2 Inhibitor, Maximally Suppresses Type 1 Interferon, a Therapeutic Pathway Central to SLE and CLE

10:30AM-12:30PM: Abstract Number: 2425

Ianalumab Induced Durable Depletion of Circulating B Cell Subsets and Associated Changes in B Cell and Neutrophil Transcriptomic and Proteomic Profiles in Patients with Systemic Lupus Erythematosus: 52-Week Treatment Results from a Phase 2 Trial

10:30AM-12:30PM: Abstract Number: 2429

Impact of Hydroxychloroquine Level on ECG QTC Interval in Patients with Rheumatic Systemic Autoimmune Diseases: A Real-life Study

10:30AM-12:30PM: Abstract Number: 2432

In Vitro and In Vivo Evidence of the Steroid-Sparing Potential of Afimetoran, an Equipotent Toll-Like Receptor 7/8 Dual Antagonist

10:30AM-12:30PM: Abstract Number: 2426

Multi-OMICs Analysis Including Lipidomics to Correlate Baseline OMICs Profiles with Disease Activity and Response to Different Immunomodulatory Treatments in Patients with Systemic Lupus Erythematosus – An Exploratory Pilot Study Using a Multi-OMICs Approach

10:30AM-12:30PM: Abstract Number: 2439

Preliminary Analysis of Open-Label Dose-Titration Phase of SLE Treatment with N-Acetylcysteine (SNAC) Shows Evidence for Potential Improvement of SLEDAI, BILAG, ADHD and Fatigue Scores in Patients with Active SLE

10:30AM-12:30PM: Abstract Number: 2438

Reduction in Oral Corticosteroid Use During Anifrolumab Therapy: Observations from a Real-world Cohort of Adults with Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 2433

Sequential Pneumococcal Vaccination in SLE: Immunogenicity, Side Effects and Comparison with PPSV23 Vaccination

10:30AM-12:30PM: Abstract Number: 2421

Trends in Glucocorticoid Use in Systemic Lupus Erythematosus in a Population-Based Inception Cohort from 1976 to 2018: The Lupus Midwest Network

10:30AM-12:30PM: Abstract Number: 2428

Vitamin-D Effect on SLE- Scoping Review

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].